Cognosci, Incorporated

The University of North Carolina at Chapel Hill

Duke University

Spyryx Biosciences, Inc.

Spryx Biosciences, Inc.

Affinergy Inc.

Dale J Christensen

Mark W Grinstaff

Paul Theodore Hamilton

Michael Peter Vitek

Robin Hyde-DeRuyscher

Ray Edward Benson

Robert Tarran

J Brice Weinberg

Jessica Oddo

Daniel J Kenan

Michael P Vitek

Brice Weinberg

Wayne Fl Beyer

The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.

Peptide inhibitors of sodium channels

The present invention provides novel pharmaceutical compositions comprising ApoE-derived peptide dimers. In particular, the ApoE peptide dimers of the invention comprise at least two ApoE mimetic domains and can comprise one or more protein transduction domains. Methods of treating various conditions, such as cancer, inflammatory conditions, and neurodegenerative diseases, by administering the pharmaceutical compositions of the invention are also disclosed.

ApoE peptide dimers and uses thereof

The present invention provides methods for modulating SET activity by contacting SET with a binding agent such as an ApoE peptide derivative. In one embodiment of the invention, a pharmaceutical composition capable of modulating SET activity is administered to a patient for the treatment of an inflammatory or neurological condition. In another embodiment of the invention, compounds efficacious for the treatment of inflammatory and neurological conditions are identified by screening for a binding agent capable of competing with or inhibiting the binding of an ApoE derivative to SET.

Methods for decreasing set in inhibiting protein phosphatase 2A (PP2A) and/or increasing the activity of cyclin-dependent kinase 5 (CDK5) by an APOE peptide

Provided are methods of predicting or assessing the level of severity of cancer or cancer progression in a patient comprising measuring levels of SET expression in a biological sample from a patient and comparing levels of SET expression to a control sample or standard value. Methods for predicting or evaluating the efficacy of a SET therapeutic and kits comprising at least one reagent for measuring SET protein expression are also provided.

Methods of diagnosing cancer

Growing community of inventors

Cary, NC, United States of America

Dale J Christensen